CHARGED ALPHA
Stock Detail
LH Healthcare Latest YouTube: Q1 2026

Labcorp

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 2026
Podcast available
Yes
Current price
$259.93
+0.93 (+0.36%)
Trailing / Forward P/E
23.04x
Forward: 13.37x
Market cap / Volume
Volume:
Revenue / Earnings Growth
5.8%
Earnings: 32.9%
Margins
10.9% op
Gross: 28.8% · Net: 6.7%
Balance sheet
1.73x current
Debt / Equity: 83.4
52-week range / Beta
$241.81 - $293.72
Beta: 0.88
Analyst target
$310.12
Upside: 19.3%
Cash / shareholder return
5.36% FCF yield
Dividend yield: 1.13%

Company context

Industry: Diagnostics & Research
Country: United States
Employees:
Price to book: 2.48x
Return on equity: 11.1%
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Price chart

Market context for LH

Competitive view

LH vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Labcorp
LH
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical
ISRG
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.
Johnson & Johnson
JNJ
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
LH
$21.31B
Labcorp
ISRG
$155.16B
Intuitive Surgical
JNJ
$564.11B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
LH
23.0x
Labcorp
ISRG
53.2x
Intuitive Surgical
JNJ
27.2x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
LH
13.4x
Labcorp
ISRG
37.2x
Intuitive Surgical
JNJ
18.4x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
LH
5.8%
Labcorp
ISRG
23.0%
Intuitive Surgical
JNJ
9.9%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
LH
32.9%
Labcorp
ISRG
18.8%
Intuitive Surgical
JNJ
-52.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
LH
10.9%
Labcorp
ISRG
30.9%
Intuitive Surgical
JNJ
27.4%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
LH
28.8%
Labcorp
ISRG
66.3%
Intuitive Surgical
JNJ
68.0%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
LH
6.7%
Labcorp
ISRG
28.1%
Intuitive Surgical
JNJ
21.8%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
LH
11.1%
Labcorp
ISRG
17.2%
Intuitive Surgical
JNJ
26.4%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
LH
5.4%
Labcorp
ISRG
1.4%
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
LH
83.41x
Labcorp
ISRG
0.50x
Intuitive Surgical
JNJ
67.73x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
LH
1.73x
Labcorp
ISRG
4.61x
Intuitive Surgical
JNJ
1.02x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
LH
0.88
Labcorp
ISRG
1.51
Intuitive Surgical
JNJ
0.26
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
LH
1.1%
Labcorp
ISRG
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
LH
19.3%
Labcorp
ISRG
30.7%
Intuitive Surgical
JNJ
7.9%
Johnson & Johnson

Episode timeline

Episode archive for LH

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
Published youtube podcast complete
LH Stock: Revenue Beats, EPS Misses — Q1 2026
Quarterly earnings-analysis entry for Labcorp. Use the links on the right to open the video or podcast episode.